(0.05%) 5 472.10 points
(0.06%) 39 134 points
(0.37%) 17 784 points
(-0.02%) $80.81
(-3.66%) $2.66
(-0.76%) $2 313.20
(0.23%) $28.94
(3.61%) $1 022.00
(0.28%) $0.936
(0.70%) $10.68
(0.45%) $0.792
(-0.28%) $87.25
Live Chart Being Loaded With Signals
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer...
Stats | |
---|---|
今日成交量 | 97 702 |
平均成交量 | 0 |
市值 | 641 019 |
EPS | $-2.16 ( Q1 | 2024-05-09 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
0 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-11-27 | Sr One Capital Management, Llc | Sell | 430 578 | Common Stock |
2023-11-27 | Sr One Capital Management, Llc | Sell | 178 585 | Common Stock |
2023-11-15 | Worland Stephen T | Buy | 5 979 | Common Stock |
2023-11-15 | Byrnes Michael | Buy | 4 524 | Common Stock |
2023-09-09 | Loewy Caroline M | Buy | 40 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
28.90 |
Last 94 transactions |
Buy: 4 047 347 | Sell: 1 063 888 |
eFFECTOR Therapeutics, 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
eFFECTOR Therapeutics, 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-111 000 (0.00 %) |
EPS: | $-16.37 |
FY | 2023 |
营收: | $0 |
毛利润: | $-111 000 (0.00 %) |
EPS: | $-16.37 |
FY | 2022 |
营收: | $3.55M |
毛利润: | $3.50M (98.51 %) |
EPS: | $-7.85 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $0 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
eFFECTOR Therapeutics,
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors and in combination with fulvestrant and abemaciclib in a Phase 2a open-label expansion cohort to treat patients with ER+ breast cancer. eFFECTOR Therapeutics, Inc. has a research collaboration and license agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。